Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study

Table 3 Baseline factors associated with clinical remission at week 52, n = 28

Factors	OR (95%CI)	P value
Age	1.003 (0.949-1.061)	0.909
Male sex	0.778 (0.173-3.493)	0.743
Montreal classification	1.500 (0.288-7.807)	0.630
Disease duration	1.030 (0.918-1.154)	0.616
Family history of IBD	1.571(0.126-19.668)	0.726
Current smoker	1.250 (0.173-9.019)	0.825
BMI	1.026 (0.906-1.163)	0.684
Extraintestinal manifestations	2.773 (0.357-14.454)	0.384
Active extraintestinal manifestation	1.571 (0.126-19.668)	0.726
Previous treatment	0.545 (0.043-6.889)	0.639
Number of previous treatments	0.636 (0.051-7.965)	0.726
Partial Mayo	1.461 (0.928-2.301)	0.102
Coadministration of 5-ASA at week 52	0.115 (0.020-0.665)	0.015a
Coadministration of steroids at week 52	0.786 (0.044-14.026)	0.870
CRP	1.002 (0.866-1.159)	0.981
Albumin	0.654 (0.132-3.247)	0.603
Hb	0.790 (0.474-1.316)	0.365
PLT	0.999 (0.992-1.006)	0.862
WBC	1.00 (1.000-1.000)	0.881
Gran	1.00 (1.000-1.001)	0.725
Endoscopic Mayo	0.383 (0.083-1.761)	0.218
Full Mayo score	1.478 (0.902-2.423)	0.121
Dose of tofacitinib at week 52	0.556 (0.106-2.901)	0.486

^aP < 0.05.

IBD: Inflammatory bowel disease; BMI: Body mass index; CRP: C-reactive protein; Hb: Hemoglobin; PLT: Platelets; WBC: White blood counts; Gran: Granulocytes; 5-ASA: 5-aminosalicylic acid; CI: Confidence interval; OR: Odds ratio.